Besins Healthcare to start series production of hormonal drugs in Russia by 2020

7 February 2018

Bangkok, Thailand-based Besins Healthcare has completed the first phase of the construction of its plant in the Novoselki industrial park of the Russian Yaroslavl region, according to the company.

As part of this, the company plans to start a full-cycle production of a new hormonal drug for women's health, named as Utrozhestan.

The drug is included in the list of vital drugs in Russia, while its purchases will be carried out by the Russian government within public procurement contracts, reports The Pharma Letter’s local correspondent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK